此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估主要抑郁症的CYB003的3阶段试验 (EMBRACE)

2026年11月12日 更新者:Cybin IRL Limited

功效和安全性,第三阶段,多中心,双盲,随机对照研究,比较了2种活跃剂量的Cyb003和安慰剂,在有严重抑郁症的合格参与者中

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

研究概览

研究类型

介入性

注册 (估计的)

330

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Athens、希腊、12462
        • 招聘中
        • Attikon University Hospital
        • 首席研究员:
          • Nikolaos Smyrnis
        • 接触:
      • Athens、希腊、11528
        • 招聘中
        • Eginitio Hospital
        • 首席研究员:
          • Nikos Stefanis
        • 接触:
      • Thessaloniki、希腊、56404
        • 招聘中
        • Papageorgiou General Hospital
        • 首席研究员:
          • Georgios Papazisis
        • 接触:
      • Berlin、德国、10117
        • 尚未招聘
        • Charité Universitaetsmedizin Berlin
        • 首席研究员:
          • Michael Koslowski
        • 接触:
      • Frankfurt am Main、德国、60528
        • 尚未招聘
        • University Hospital Frankfurt
        • 首席研究员:
          • Andreas Reif
        • 接触:
      • Mannheim、德国、68159
        • 尚未招聘
        • Central Institute of Mental Health
        • 接触:
        • 首席研究员:
          • Gerhard Grüender
    • Saarland
      • Homburg、Saarland、德国、66421
        • 尚未招聘
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • 首席研究员:
          • Matthias Riemenschneider
        • 接触:
        • 接触:
      • Prague、捷克语
        • 尚未招聘
        • Institute of neuropsychiatric Care (INEP)
        • 首席研究员:
          • Alexander Nawka
        • 接触:
      • Prague、捷克语
        • 尚未招聘
        • Psyon s.r.o.
        • 首席研究员:
          • Tomas Palenicek
        • 接触:
      • Předměstí、捷克语
        • 尚未招聘
        • A-SHINE s.r.o.
        • 首席研究员:
          • Lubos Janu
        • 接触:
      • Bialystok、波兰、15-272
        • 撤销
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz、波兰、85-133
        • 招聘中
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • 接触:
        • 首席研究员:
          • Katarzyna Lachut
      • Gdansk、波兰、80-546
        • 招聘中
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • 接触:
        • 首席研究员:
          • Hanna Badzio-Jagiello
      • Gdansk、波兰、80-214
        • 尚未招聘
        • UCK
        • 首席研究员:
          • Wieslaw Jerzy Cubala
        • 接触:
      • Warsaw、波兰、02-957
        • 尚未招聘
        • Department of Pharmacology and Physiology of CNS
        • 首席研究员:
          • Justyna Holka-Pokorska
      • Warsaw、波兰、02-172
        • 招聘中
        • MTZ Clinical Research Powered by Pratia
        • 首席研究员:
          • Monika Gawlowicz
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
        • 招聘中
        • Royal Prince Alfred Hospital
        • 首席研究员:
          • Nicholas Glozier
    • Queensland
      • Maroochydore、Queensland、澳大利亚、4558
        • 招聘中
        • Thompson Brain & Mind Healthcare (TBMH)
        • 首席研究员:
          • Adem Can
        • 接触:
        • 接触:
    • Victoria
      • Melbourne、Victoria、澳大利亚、3004
      • Melbourne、Victoria、澳大利亚、3053
      • Notting Hill、Victoria、澳大利亚、3168
        • 招聘中
        • Monash University - Notting Hill
        • 接触:
        • 首席研究员:
          • Paul Liknaitzky
      • Dublin、爱尔兰、D24 WK80
        • 招聘中
        • Sheaf House - Tallaght Adult Mental Health Service
        • 首席研究员:
          • John Kelly
        • 接触:
      • Galway、爱尔兰、H91 VE03
        • 招聘中
        • La Nua Day Hospital Mental Health Centre
        • 接触:
        • 首席研究员:
          • Shane McInerney
    • Alabama
      • Birmingham、Alabama、美国、35209
        • 招聘中
        • UAB Psychiatry and Behavioral Neurology
        • 接触:
        • 首席研究员:
          • Peter Hendricks
        • 接触:
    • Arizona
      • Gilbert、Arizona、美国、85234
    • Arkansas
      • Little Rock、Arkansas、美国、72204
        • 撤销
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale、California、美国、91206
        • 招聘中
        • Behavioral Research Specialists, LLC
        • 首席研究员:
          • Jesse Carr
        • 接触:
      • Imperial、California、美国、92251
        • 撤销
        • Sun Valley Research Center
      • Los Angeles、California、美国、90025
        • 招聘中
        • CalNeuro Research Group
        • 首席研究员:
          • Alexander Bystritsky
        • 接触:
      • Los Angeles、California、美国、90025
      • Orange、California、美国、92868
        • 招聘中
        • NRC Research Institute
        • 接触:
        • 首席研究员:
          • Daniel Chueh
      • Orange、California、美国、92866
        • 招聘中
        • ATP Clinical Research
        • 首席研究员:
          • Gustavo Alva
        • 接触:
      • San Juan Capistrano、California、美国、92675
        • 招聘中
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • 首席研究员:
          • Neelima Kunam
        • 接触:
      • Santa Monica、California、美国、90404
        • 招聘中
        • Psychedelic Science Institute
        • 首席研究员:
          • Keith Heinzerling
        • 接触:
      • Stanford、California、美国、94305
        • 撤销
        • Stanford University
    • Connecticut
      • New Haven、Connecticut、美国、06511
        • 招聘中
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • 首席研究员:
          • Ben Kelmendi
        • 接触:
          • Daidre Chamberlain
          • 电话号码:203-693-1591
          • 邮箱:enact@yale.edu
        • 接触:
    • Florida
      • Jacksonville、Florida、美国、32256
        • 招聘中
        • CNS Healthcare
        • 接触:
          • 电话号码:904-281-5757
        • 首席研究员:
          • John Mark Joyce
      • Maitland、Florida、美国、32751
        • 招聘中
        • Accel Research Sites - Maitland
        • 接触:
          • 电话号码:407-644-1165
        • 首席研究员:
          • Andrea Marrafino
      • Naples、Florida、美国、34105
        • 招聘中
        • Aqualane Clinical Research
        • 首席研究员:
          • Matthew Baker
        • 接触:
      • Tampa、Florida、美国、33634
        • 招聘中
        • K2 Medical Research Tampa
        • 首席研究员:
          • Kelley Wilson
        • 接触:
    • Georgia
      • Atlanta、Georgia、美国、30329
        • 撤销
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta、Georgia、美国、30060
        • 招聘中
        • Psych Atlanta
        • 首席研究员:
          • Michael Banov
        • 接触:
    • Illinois
      • Chicago、Illinois、美国、60612
        • 招聘中
        • Rush University
        • 首席研究员:
          • Joshua Eloge
        • 接触:
    • Louisiana
      • Marrero、Louisiana、美国、70006
        • 撤销
        • Tandem Clinical Research
      • New Orleans、Louisiana、美国、70115
        • 招聘中
        • Atlas Psychiatry
        • 接触:
        • 首席研究员:
          • Nicholas Pejic
    • Maryland
      • Baltimore、Maryland、美国、21224
        • 撤销
        • Johns Hopkins Medicine
      • Rockville、Maryland、美国、20850
    • Massachusetts
      • Boston、Massachusetts、美国、02116
        • 招聘中
        • Adams Clinical Boston
        • 首席研究员:
          • Darin Dougherty
        • 接触:
      • Watertown、Massachusetts、美国、02472
        • 招聘中
        • Adams Clinical Watertown
        • 首席研究员:
          • Stephanie Ellickson
        • 接触:
    • Minnesota
      • Eden Prairie、Minnesota、美国、55347
        • 招聘中
        • Institute for Integrative Therapies
        • 首席研究员:
          • Manoj Doss
        • 接触:
      • Golden Valley、Minnesota、美国、55427
        • 尚未招聘
        • The Remedy Mental Health
        • 接触:
        • 首席研究员:
          • Wayne Bentham
    • Nevada
      • Las Vegas、Nevada、美国、89119
        • 招聘中
        • Redbird Research, LLC
        • 首席研究员:
          • Jelena Kunovac
        • 接触:
    • New Jersey
      • Toms River、New Jersey、美国、08755
        • 招聘中
        • Bio Behavioral Health
        • 接触:
        • 首席研究员:
          • Ashok Patel
    • New York
      • New York、New York、美国、10032
        • 尚未招聘
        • New York State Psychiatric Institute
        • 首席研究员:
          • Natalie Gukasyan
        • 接触:
      • New York、New York、美国、10029
        • 招聘中
        • Adams Clinical Harlem
        • 接触:
        • 首席研究员:
          • Wesley Gregory
      • The Bronx、New York、美国、10461
        • 招聘中
        • Adams Clinical Bronx
        • 首席研究员:
          • Shama Farooq
        • 接触:
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73112
        • 撤销
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Adams Clinical Philadelphia
        • 首席研究员:
          • Cassie Blanchard
        • 接触:
      • Philadelphia、Pennsylvania、美国、19462
        • 招聘中
        • Flourish Research Philadelphia
        • 首席研究员:
          • Rachna Saralkar
        • 接触:
          • 电话号码:215-614-5606
    • Texas
      • Austin、Texas、美国、78737
        • 撤销
        • Austin Clinical Trial Partners
      • DeSoto、Texas、美国、75115
        • 招聘中
        • Adams Clinical Dallas
        • 首席研究员:
          • Rajinder Shiwach
        • 接触:
      • Fort Worth、Texas、美国、76104
        • 撤销
        • North Texas Clinical Trials
      • Houston、Texas、美国、77046
        • 招聘中
        • Brain Health Consultants and TMS Center
        • 首席研究员:
          • Lauren Marangell
        • 接触:
      • San Antonio、Texas、美国、78229
    • Washington
      • Everett、Washington、美国、98201
        • 尚未招聘
        • Core Clinical Research
        • 接触:
        • 首席研究员:
          • James Knutson
      • Seattle、Washington、美国、98104
        • 招聘中
        • Seattle Neuropsychiatric Treatment Center
        • 首席研究员:
          • Rebecca Allen
        • 接触:
      • Cambridge、英国、CB1 2EU
        • 招聘中
        • Cambridge University Hospital NHS
        • 首席研究员:
          • Liliana Galindo
        • 接触:
        • 接触:
      • Doncaster、英国、DN4 8QN
        • 招聘中
        • Clerkenwell Health - Doncaster
        • 首席研究员:
          • Paul Morrison
        • 接触:
      • Edinburgh、英国、EH16 4TJ
        • 尚未招聘
        • NHS Research Scotland
        • 首席研究员:
          • Donald MacIntyre
        • 接触:
      • Glasgow、英国、G51 4TF
      • Liverpool、英国、L7 8XP
        • 尚未招聘
        • Royal Liverpool Hospital
        • 接触:
        • 首席研究员:
          • Fabian Devlin
      • London、英国、EC2Y 8EA
        • 招聘中
        • St Pancras Clinical Research
        • 首席研究员:
          • Martin Johnson
        • 接触:
      • London、英国、W1U 6RP
      • London、英国、W1G9 RU
        • 招聘中
        • Re:Cognition Health
        • 首席研究员:
          • Dimitrios Paschos
        • 接触:
          • 电话号码:+44-0800-802-1030
      • London、英国、SE5 9RS
      • London、英国、W1G 8DR
        • 撤销
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne、英国、NE4 5PL
      • Reading、英国、RG7 8PA
        • 招聘中
        • Ascend Clinical Research
        • 首席研究员:
          • Pamela Walters
        • 接触:
      • Sheffield、英国、S4 7QQ

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

实验性的:Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

安慰剂比较:Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Montgomery-Asberg Depression Scale (MADRS)
大体时间:Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

次要结果测量

结果测量
措施说明
大体时间
The Beck Depression Inventory - Second Edition (BDI-II)
大体时间:Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
大体时间:Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
大体时间:Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
大体时间:Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Felix Mazer、Cybin IRL Limited

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月10日

初级完成 (估计的)

2027年6月7日

研究完成 (估计的)

2027年8月9日

研究注册日期

首次提交

2025年1月21日

首先提交符合 QC 标准的

2025年1月21日

首次发布 (实际的)

2025年1月27日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅